Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
22nd Century Group Inc. develops and commercializes reduced-nicotine tobacco products built on proprietary plant biotechnology. Its VLN® combustible cigarette products use low-nicotine tobacco and are described in company materials as FDA-authorized reduced nicotine cigarettes in the United States. Company updates commonly address VLN retail distribution, state authorizations, PMTA-related product expansion, licensing strategy, tobacco-variety research and engagement with FDA and public-health stakeholders.
News also covers operating results for the tobacco business, including branded VLN products, contract manufacturing volumes, filtered cigars and other distributed tobacco products. Recent company reporting frames results around commercial expansion, cost management, higher-margin branded products and the completed exit from the hemp/cannabis business.
22nd Century Group (Nasdaq: XXII) announced that its VLN® King and VLN® Menthol King reduced nicotine content cigarettes received FDA marketing authorization as modified risk tobacco products (MRTPs). VLN® cigarettes contain 95% less nicotine than traditional cigarettes and are aimed at helping smokers reduce nicotine exposure and consumption. The FDA approved claims such as 'Helps you smoke less' and '95% less nicotine.' With 60% of adult smokers expressing interest in trying VLN®, the company plans to launch these products in the U.S. within 90 days and globally by Q1 2022.
22nd Century Group (Nasdaq: XXII), has received FDA MRTP designation for its VLN® cigarettes, the first combustible cigarette to obtain this status. The FDA authorized claims including “Helps you smoke less” and “95% less nicotine.” VLN® is set to launch in the U.S. within 90 days and internationally in Q1 2022. With 60% of adult smokers indicating a willingness to try VLN®, this could significantly transform tobacco use and public health.
Aurora Cannabis (ACB) and 22nd Century Group (XXII) announced a licensing agreement with Cronos Group (CRON) to advance cannabinoid biosynthesis research. This non-exclusive deal aims to enhance the production of rare cannabinoids such as CBG, CBC, and CBN efficiently and with high purity. According to CEO Miguel Martin, the collaboration is a significant step towards commercializing cannabinoid products, which could benefit health and wellness applications. Aurora and 22nd Century also plan to enforce their intellectual property rights against infringements.
The New Zealand Ministry of Health has announced a reduced nicotine mandate by 2025 as part of its Smokefree Aotearoa 2025 Action Plan. 22nd Century Group (Nasdaq: XXII) supports this initiative, preparing to supply reduced nicotine content (RNC) cigarettes that contain 95% less nicotine than conventional options. The company's VLN® cigarettes align with the government’s goal to reduce smoking prevalence, particularly among vulnerable communities. Additionally, 22nd Century aims to launch VLN® sales internationally in early 2022, enhancing its market position to cater to growing public health demands.
22nd Century Group, Inc. (Nasdaq: XXII) announced the appointment of Richard Fitzgerald as Chief Financial Officer effective November 15, 2021. He succeeds John Franzino, who transitions to Chief Administrative Officer, focusing on enhancing business processes. CEO James A. Mish emphasized the critical timing for leadership expansion amid the upcoming MRTP authorization and international launch of the VLN® product. Fitzgerald brings substantial experience in IP and technology licensing, aiming to leverage this for the company's growth across its plant franchises, including tobacco, hemp/cannabis, and hops.
22nd Century Group (Nasdaq: XXII) expresses strong support for Dr. Robert Califf’s nomination as FDA Commissioner. Califf, a proponent of tobacco control, emphasizes a nicotine cap as a crucial priority for public health. The company’s reduced nicotine cigarette, VLN®, aligns with FDA's proposed nicotine mandate, which could significantly assist over five million smokers in quitting within the first year. With MRTP designation for VLN® being a top priority, the company is poised for a U.S. launch within 90 days post-approval, aiming for international expansion in early 2022.
22nd Century Group (Nasdaq: XXII) announced its participation in two virtual investor conferences in November 2021. The first event is the Inaugural Roth Capital Partners AgTech Answers Virtual Event on November 16, allowing meetings with company representatives. The second event is the Cowen 4th Annual Cannabis Conference on November 30, featuring a panel discussion titled 'Creative Cannabis Exposure.' Interested attendees can request meetings through the respective conference hosts or the company's investor relations team.
22nd Century Group (Nasdaq: XXII) reported third-quarter 2021 net sales of $7.8 million, up 6.9% year-over-year, driven by increased contract manufacturing. The company holds a strong cash position of $55.2 million as of September 30, 2021. After a successful October 14 meeting with the FDA, confidence in obtaining MRTP authorization for its VLN® reduced nicotine cigarettes is at an all-time high. Plans include monetizing hemp/cannabis lines starting Q4 2021 and launching a new hops franchise, expanding its addressable market to $1.3 trillion.
22nd Century Group, trading as XXII, will host a live webcast on November 4, 2021, at 10:00 AM ET to discuss its third quarter 2021 results. The report will be released at 6:00 AM ET on the same day. CEO James A. Mish, COO Michael Zercher, and CFO John Franzino will review performance and progress across the company’s three franchises. Following their presentation, a Q&A session will allow analysts and stakeholders to ask questions. Access the webcast and related materials on the company’s investor relations website.
22nd Century Group (Nasdaq: XXII) commends the FDA for its recent actions supporting reduced nicotine alternatives, affirming its commitment to public health. The company’s VP of Regulatory Science, John Pritchard, is set to speak at the FDLI Tobacco and Nicotine Products Regulation and Policy Conference on October 27, 2021. The FDA's Comprehensive Plan aims to lower nicotine in all cigarettes to non-addictive levels. 22nd Century’s VLN® cigarettes contain significantly less nicotine and could greatly impact smoking cessation efforts, potentially saving millions of lives.